Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

23.21 +0.35 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 408,215
Open 23.00
Bid (Size) 23.21 (1,400)
Ask (Size) 23.24 (300)
Prev. Close 22.86
Today's Range 23.00 - 23.65
52wk Range 18.80 - 27.64
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health ↗
Via Chartmill
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
From Pacira BioSciences
Via GlobeNewswire

Performance

YTD
-5.1%
-5.1%
1 Month
+2.1%
+2.1%
3 Month
+4.4%
+4.4%
6 Month
-5.0%
-5.0%
1 Year
-8.7%
-8.7%

More News

Read More
News headline image
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
From Biotech Insider
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety ↗
Via Chartmill
Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near ↗
Via Chartmill
News headline image
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
From Pacira BioSciences
Via GlobeNewswire
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
From World Street Intelligence
Via GlobeNewswire
News headline image
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pacira (PCRX) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Pacira BioSciences Reports First Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
Via MarketMinute
News headline image
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 23.21
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 06/09/26 04:00 PM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.03B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.